Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) kicked off on Monday, up 5.27% from the previous trading day, before settling in for the closing price of $7.78. Over the past 52 weeks, BCRX has traded in a range of $4.03-$8.88.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 190.00%. While this was happening, its average annual earnings per share was recorded 68.05%. With a float of $196.10 million, this company’s outstanding shares have now reached $205.77 million.
Let’s determine the extent of company efficiency that accounts for 536 employees. In terms of profitability, gross margin is 97.91%, operating margin of -9.84%, and the pretax margin is -30.09%.
Biocryst Pharmaceuticals Inc (BCRX) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Biocryst Pharmaceuticals Inc is 5.32%, while institutional ownership is 83.49%. The most recent insider transaction that took place on Jun 24 ’24, was worth 54,352. In this transaction Director of this company sold 8,600 shares at a rate of $6.32, taking the stock ownership to the 27,831 shares. Before that another transaction happened on Jun 17 ’24, when Company’s Director sold 4,689 for $6.00, making the entire transaction worth $28,134. This insider now owns 27,742 shares in total.
Biocryst Pharmaceuticals Inc (BCRX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 68.05% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 44.80% during the next five years compared to -3.73% drop over the previous five years of trading.
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) Trading Performance Indicators
Take a look at Biocryst Pharmaceuticals Inc’s (BCRX) current performance indicators. Last quarter, stock had a quick ratio of 2.73. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.17.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.61, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.07 in one year’s time.
Technical Analysis of Biocryst Pharmaceuticals Inc (BCRX)
Looking closely at Biocryst Pharmaceuticals Inc (NASDAQ: BCRX), its last 5-days average volume was 2.67 million, which is a drop from its year-to-date volume of 2.97 million. As of the previous 9 days, the stock’s Stochastic %D was 64.89%. Additionally, its Average True Range was 0.41.
During the past 100 days, Biocryst Pharmaceuticals Inc’s (BCRX) raw stochastic average was set at 76.04%, which indicates a significant decrease from 84.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 83.75% in the past 14 days, which was higher than the 52.38% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.75, while its 200-day Moving Average is $6.49. However, in the short run, Biocryst Pharmaceuticals Inc’s stock first resistance to watch stands at $8.34. Second resistance stands at $8.48. The third major resistance level sits at $8.72. If the price goes on to break the first support level at $7.96, it is likely to go to the next support level at $7.72. Should the price break the second support level, the third support level stands at $7.58.
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) Key Stats
The company with the Market Capitalisation of 1.72 billion has total of 207,133K Shares Outstanding. Its annual sales at the moment are 331,410 K in contrast with the sum of -226,540 K annual income. Company’s last quarter sales were recorded 109,330 K and last quarter income was -12,670 K.
